Cellular Actions of Parathyroid Hormone

Principles of Bone Biology: Volume 1-2, Third Edition

Volumn , Issue , 2008, Pages 639-656

  Kousteni, Stavroula ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61849151563     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00049-5     Document Type: Chapter

References (236)

1. Alvarez, et al. (1998) PTH-responsive osteoblast nuclear matrixarchitectural transcription factor binds to the rat type I collagen promoter. J. Cell Biochem. 69(3), 336-352.
2. M. Babich, et al. (1991) Thrombin and parathyroid hormone mobilize intracellular calcium in rat osteosarcoma cells by distinct pathways. Endocrinology 129(3), 1463-1470.
3. G.L. Barnes, S. Kakar, L.C. Gerstenfeld and T.A. Einhorn (2005) PTH mediates early stem cell recruitment during fracture repair. J. Bone Miner Res. 20(suppl. 1), S102.
4. N. Barnicott (1948) The local action of the parathyroid and other tissues on bone in intracerebral grafts. J. Anat 82 233-248.
5. T. Bellido, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11), 4577-4583.
6. T. Bellido, et al. (2005) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts, A putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem. 278(50), 50259-50272.
7. T. Bellido, et al. (1998) Transcriptional activation of the p21WAF1, CIP1, SDI1 gene by interleukin-6 type cytokines: A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J. Biol. Chem. 273(33), 21137-21144.
8. J.P. Bidwell, et al. (1998) Nuclear matrix proteins and osteoblast gene expression. J. Bone Miner. Res 13(2), 155-167.
9. D.D. Bikle, et al. (2002) Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J. Bone Miner. Res 17(9), 1570-1578.
10. D.M. Black, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207-1215.
11. P.V. Bodine, et al. (2007) Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell Physiol. 210(2), 352-357.
12. P.V.N. Bodine, Y.P. Kharode, L. Seestaller-Wehr, P. Green, C. Milligan and F.J. Bex (2004) The bone anabolic effects of parathyroid hormone (PTH) are blunted by deletion of the Wnt antagonist secreted frizzled-related protein (sFRP)-1. J. Bone Miner. Res 19(suppl. 1), S17.
13. Z. Bogdanovic (2000) Parathyroid hormone inhibits collagen synthesis and the activity of rat col1a1 transgenes mainly by a cAMPmediated pathway in mouse calvariae. J. Cell Biochem. 77(1), 149-158.
14. T. Bretschneider, B. Vasiev and C.J. Weijer (1997) A model for cell movement during dactyloctenium mound formation. J. Theor. Biol. 189(1), 41-51.
15. M.E. Brunkow, et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68(3), 577-589.
16. D.B. Burr, et al. (2001) Intermittently administered human parathyroid hormone (1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16(1), 157-165.
17. R.B. Burrows (1938) Variations produced in bones of growing rats by parathyroid extract. Am. J. Anat. 62 237-290.
18. E.C. Buxton, W. Yao and N.E. Lane (2004) Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1–34). J. Clin. Endocrinol. Metab. 89(7), 3332-3336.
19. L.M. Calvi, et al. (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107(3), 277-286.
20. E. Canalis, et al. (1989) Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest 83(1), 60-65.
21. E. Canalis, J.M. Hock and L.G. Raisz (1994) Anabolic and catabolic effects of parathyroid hormone on bone and interactions with growth factors. J.P. Bilezikian, M.A. Levine (Eds) The Parathyroids New York: Raven Press
22. G.K. Chan, et al. (2001) PTHrP inhibits adipocyte differentiation by downregulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology 142(11), 4900-4909.
23. H.L. Chen, et al. (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J. Biol. Chem 277(22), 19374-19381.
24. J.W. Chow, et al. (1998) Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol 274(1 Pt 1), E146-E154.
25. R. Civitelli, et al. (1989) Second messenger signaling in the regulation of collagenase production by osteogenic sarcoma cells. Endocrinology 124(6), 2928-2934.
26. R. Civitelli, et al. (1990) Cyclic AMP-dependent and calcium-dependent signals in parathyroid hormone function. Exp. Gerontol 25(3–4), 223-231.
27. R. Civitelli, et al. (1988) PTH elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell line. Am. J. Physiol. 255(5 Pt 1), E660-E667.
28. J.C. Clohisy, et al. (1992) Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol. Endocrinol.6 1834-1842.
29. J.A. Cole (1999) Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 140(12), 5771-5779.
30. C.A. Conover (2000) Insulin-like growth factors and the skeleton. E. Canalis (Eds) Skeletal Growth Factors Philadelphia: Lippincott Williams & Wilkins
31. J. Cornish, et al. (1999) Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J. Bone Miner. Res. 14(6), 915-922.
32. F. Cosman and R. Lindsay (1998) Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif. Tissue Int. 62(6), 475-480.
33. F. Cosman and R. Lindsay (1998) Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif. Tissue Int 62(6), 475-480.
34. F. Cosman, et al. (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13(6), 1051-1055.
35. F. Cosman, et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353(6), 566-575.
36. F. Cosman, et al. (1991) Response of the parathyroid gland to infusion of human parathyroid hormone-(1–34) [PTH-(1–34)]: Demonstration of suppression of endogenous secretion using immunoradiometric intact PTH- (1–84) assay. J. Clin. Endocrinol. Metab 73 1345-1351.
37. N.S. Datta, et al. (2005) PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J. Bone Miner. Res. 20(6), 1051-1064.
38. N.S. Datta, et al. (2007) Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J. Bone Miner. Res. 22(7), 951-964.
39. P.D. Delmas, et al. (1995) The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate: Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16 603-610.
40. D.W. Dempster, et al. (1993) Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 14 690-709.
41. J.W. Dietrich, et al. (1976) Hormonal control of bone collagen synthesis in vitro: Effects of parathyroid hormone and calcitonin. Endocrinology 98(4), 943-949.
42. P. Divieti, et al. (2001) Receptors for the carboxyl-terminal region of PTH (1–84) are highly expressed in osteocytic cells. Endocrinology 142(2), 916-925.
43. H. Dobnig and R.T. Turner (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 3632-3638.
44. H. Dobnig and R.T. Turner (1997) The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138(11), 4607-4612.
45. J.A. Elias, W. Tang and M.C. Horowitz (1995) Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology 136 489-498.
46. D.L. Ellies, et al. (2006) Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21(11), 1738-1749.
47. B. Ettinger, et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res 19(5), 745-751.
48. H.A. Feister, et al. (2000) The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha, and -beta in bone and osseous cell culture: Regulation by parathyroid hormone. Bone. 26(3), 227-234.
49. J.S. Finkelstein, et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med 349(13), 1216-1226.
50. C.J. Fiol, et al. (1994) A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem 269(51), 32187-32193.
51. S.M. Frisch (2000) cAMP takes control. Nat. Cell Biol 2(9), E167-E168.
52. C.A. Frolik, et al. (2003) Anabolic and catabolic bone effects of human parathyroid hormone (1–34) are predicted by duration of hormone exposure. Bone. 33(3), 372-379.
53. Q. Fu, et al. (2002) Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277(50), 48868-48875.
54. Q. Fu, S.C. Manolagas and C.A. O’Brien (2006) Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol. Cell Biol. 26(17), 6453-6468.
55. K. Fuller, J.M. Owens and T.J. Chambers (1998) Induction of osteoclast formation by parathyroid hormone depends on an action on stromal cells. J Endocrinol 158(3), 341-350.
56. K. Fuller, et al. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188(5), 997-1001.
57. A.L. Gartel and A.L. Tyner (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther 1(8), 639-649.
58. R.C. Gensure, T.J. Gardella and H. Juppner (2005) Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem. Biophys. Res. Commun. 328(3), 666-678.
59. D. Gesty-Palmer, et al. (2006) Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281(16), 10856-10864.
60. D.A. Glass, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell. 8(5), 751-764.
61. E.M. Greenfield, M.C. Horowitz and S.A. Lavish (1996) Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem.271 10984-10989.
62. E.M. Greenfield, et al. (1995) Adenyl cyclase and interleukin-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest 96 1238-1244.
63. A. Grey, et al. (2003) Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 144(11), 4886-4893.
64. A. Grey, et al. (1999) A role of interleukin-6 in parathyroid hormoneinducedbone resorption. in vivo Endocrinology 140(10), 4683-4690.
65. A.E. Grigoriadis, et al. (1994) c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266(5184), 443-448.
66. M. Gunness and E. Orwoll (1995) Early induction of alterations in cancellous and cortical bone histology after orchiectomy in mature rats. J. Bone Miner. Res. 10(11), 1735-1744.
67. J. Guo, E. Schipani, M. Liu, F.R. Bringhurst and H.M. Kronenberg (2005) Suppression of Dkk1 is not essential for PTH-mediated activation of canonical Wnt signaling in bone. J. Bone Miner. Res. 20(suppl. 1), S2.
68. H. Heath (1996) Primary hyperparathyroidism, hyperparathyroid bone disease, and osteoporosis. Osteoporosis New York: Academic Press
69. T. Hirano, et al. (2000) Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1–34). Calcif. Tissue Int 66(6), 456-460.
70. T. Hirano, et al. (1999) Anabolic effects of human biosynthetic parathyroid hormone fragment (1–34): LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J. Bone Miner. Res. 14(4), 536-545.
71. J.M. Hock and J. Fonseca (1990) Anabolic effect of human synthetic parathyroid hormone-(1–34) depends on growth hormone. Endocrinology 127 1804-1810.
72. J.M. Hock and I. Gera (1992) Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res. 7 65-72.
73. A.B. Hodsman and B.M. Steer (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14 523-527.
74. A.M. Hofer, et al. (2000) Intercellular communication mediated by the extracellular calcium-sensing receptor. Nat. Cell Biol. 2(7), 392-398.
75. N.J. Horwood, et al. (1998) Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139(11), 4743-4746.
76. G.A. Howard, et al. (1981) Parathyroid hormone stimulates bone formation and resorption in organ culture: Evidence for a coupling mechanism. Proc. Natl. Acad. Sci. U. S. A. 78(5), 3204-3208.
77. A.K. Howe and R.L. Juliano (2000) Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase. Nat. Cell Biol 2(9), 593-600.
78. J.C. Huang, et al. (2004) PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res. 19(2), 235-244.
79. Y.F. Huang, et al. (1998) Parathyroid hormone induces interleukin-6 heterogeneous nuclear and messenger RNA expression in murine calvarial organ cultures. Bone 23(4), 327-332.
80. M.M. Hurley, et al. (2006) Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2+/- mice. Biochem. Biophys. Res. Commun. 341(4), 989-994.
81. M.M. Hurley, et al. (1999) Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J. Bone Miner. Res 14(5), 776-783.
82. A. Iida-Klein, et al. (2007) Effects of cyclic vs. daily treatment with human parathyroid hormone (1–34) on murine bone structure and cellular activity. Bone 40(2), 391-398.
83. T. Ishizuya, et al. (1997) Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99(12), 2961-2970.
84. U.T. Iwaniec, et al. (2007) PTH stimulates bone formation in mice deficient in Lrp5. J. Bone Miner. Res. 22(3), 394-402.
85. H. Jaffe (1933) Hyperparathyroidism (Recklinghausen’s disease of bone). Arch. Pathol. Lab. Med. 16 63-122.
86. R.L. Jilka (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40(6), 1434-1446.
87. R.L. Jilka, et al. (1998) Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines. J.Bone Miner. Res. 13 793-802.
88. R.L. Jilka, et al. (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest 104(4), 439-446.
89. W. Jochum, et al. (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6(9), 980-984.
90. R.S. Johnson, B.M. Spiegelman and V. Papaioannou (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71(4), 577-586.
91. S. Kakar, et al. (2007) Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J. Bone Miner. Res 22(12), 1903-1912.
92. J. Kano, et al. (1994) Second messenger signaling of c-fos gene induction by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: Its role in osteoblast proliferation and osteoclast-like cell formation. J. Cell Physiol 161(2), 358-366.
93. M. Kanzawa, et al. (2000) Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur. J. Endocrinol 142(6), 661-664.
94. K. Masaki Kato, et al. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol 157(2), 303-314.
95. H. Keller and M. Kneissel (2005) SOST is a target gene for PTH in bone. Bone 37(2), 148-158.
96. N.F. Kember (1960) Cell division in endochondral ossification. A study of cell proliferation in rat bones by the method of tritiated thymidine autoradiography. J. Bone Joint Surg. Br. 42B 824-839.
97. S. Khosla (2001) Minireview: The OPG/RANKL/RANK system. Endocrinology 142(12), 5050-5055.
98. D.B. Kimmel and W.S. Jee (1980) Bone cell kinetics during longitudinal bone growth in the rat. Calcif. Tissue Int 32 123-133.
99. R. Kitazawa, et al. (1991) Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: Comparative study by histomorphometry. Bone Miner 12(3), 157-166.
100. E. Knopp, et al. (2005) The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146(4), 1983-1990.
101. H. Kondo, J. Guo and F.R. Bringhurst (2002) Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17(9), 1667-1679.
102. B.E. Kream, et al. (1993) Parathyroid hormone represses alpha 1(I) collagen promoter activity in cultured calvariae from neonatal transgenic mice. Mol. Endocrinol 7(3), 399-408.
103. B.E. Kream, et al. (1993) Parathyroid hormone represses alpha 1(I) collagen promoter activity in cultured calvariae from neonatal transgenic mice. Mol. Endocrinol 7(3), 399-408.
104. M.H. Kroll (2000) Parathyroid hormone temporal effects on bone formation and resorption. Bull. Math. Biol 62(1), 163-188.
105. N.H. Kulkarni, et al. (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell Biochem 95(6), 1178-1190.
106. N.E. Lane, et al. (2003) Both hPTH(1–34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture. J. Bone Miner. Res. 18(12), 2105-2115.
107. M.C. Langub, et al. (2001) Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J. Bone Miner. Res. 16(3), 448-456.
108. D. LaTour, et al. (1990) Inhibitory insulin-like growth factor-binding protein: cloning, complete sequence, and physiological regulation. Mol. Endocrinol. 4(12), 1806-1814.
109. D. Leaffer, et al. (1995) Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide- (1–34): and bovine PTH-(1–34). Endocrinology 136 3624-3631.
110. K. Lee, et al. (1993) In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats. Bone 14 341-345.
111. S.K. Lee and J.A. Lorenzo (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140(8), 3552-3561.
112. S.K. Lee and J.A. Lorenzo (2002) Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures. Bone 31(1), 252-259.
113. O. Leupin, et al. (2007) Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner. Res 22(12), 1957-1967.
114. X. Li, et al. (2007) Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J. Biol. Chem. 282(45), 33086-33097.
115. X. Li, et al. (2007) Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J. Biol. Chem. 282(45), 33098-33106.
116. J.D. Liang, et al. (1999) Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1–34. Calcif. Tissue Int 65(5), 369-373.
117. R. Lindsay, et al. (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J. Bone Miner. Res 21(3), 366-373.
118. R. Lindsay, et al. (1993) Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): Kinetics and biochemical response in estrogenized osteoporotic patients. J. Clin. Endocrinol. Metab 77: 1535-1539.
119. R. Lindsay, et al. (2007) Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner. Res 22(4), 495-502.
120. F. Liu, et al. (2007) CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone 40(4), 1135-1143.
121. R.M. Locklin, et al. (2003) Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell Biochem. 89(1), 180-190.
122. G.G. Loots, et al. (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15(7), 928-935.
123. J.A. Lorenzo, et al. (2006) Anabolic responses of bone to parathyroid hormone are maintained in mice with deficient osteoclast formation and activity. J. Bone Miner. Res 21(suppl. 1), S52.
124. R.A. Luben, G.L. Wong and D.V. Cohn (1976) Biochemical characterization with parathormone and calcitonin of isolated bone cells: Provisional identification of osteoclasts and osteoblasts. Endocrinology 99(2), 526-534.
125. Y.L. Ma, et al. (2003) New bone formation with teriparatide [human parathyroid hormone-(1–34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144(5), 2008-2015.
126. Y.L. Ma, et al. (2001) Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142(9), 4047-4054.
127. Y.L. Ma, et al. (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res. 21(6), 855-864.
128. B.R. MacDonald, J.A. Gallagher and R.G. Russell (1986) Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118(6), 2445-2449.
129. R.J. Majeska and G.A. Rodan (1982) Alkaline phosphatase inhibition by parathyroid hormone and isoproterenol in a clonal rat osteosarcoma cell line. Possible mediation by cyclic AMP. Calcif. Tissue Int. 34(1), 59-66.
130. H.H. Malluche, et al. (1982) Effects of long-term infusion of physiologic doses of 1– 34 PTH on bone. Am. J. Physiol 242 F197-F201.
131. T.J. Martin and N.A. Sims (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med 11(2), 76-81.
132. T. Mashiba, et al. (2001) Effects of human parathyroid hormone (1–34): LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone. 28(5), 538-547.
133. T.L. McCarthy, et al. (1994) Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: Regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors. J. Cell Physiol 160(1), 163-175.
134. L.K. McCauley, et al. (1997) Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology 138(12), 5427-5433.
135. P. McClelland, et al. (1998) Intermittent administration of parathyroid hormone (1–34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. J. Cell. Biochem 70(3), 391-401.
136. P.M. McSheehy and T.J. Chambers (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118: 824-828.
137. D.C. Mears (1971) Effects of parathyroid hormone and thyrocalcitonin on the membrane potential of osteoclasts. Endocrinology 88(4), 1021-1028.
138. X.W. Meng, et al. (1996) Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11 421-429.
139. D. Miao, et al. (2001) Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 276(34), 32204-32213.
140. R.J. Midura, et al. (2003) Parathyroid hormone rapidly stimulates hyaluronan synthesis by periosteal osteoblasts in the tibial diaphysis of the growing rat. J. Biol. Chem 278(51), 51462-51468.
141. R.R. Miles, et al. (2002) Parathyroid hormone (hPTH 1–38) stimulates the expression of UBP41, an ubiquitin-specific protease, in bone. J. Cell Biochem. 85(2), 229-242.
142. N. Miyakoshi, et al. (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142(10), 4349-4356.
143. T. Moriwake, et al. (1992) 1, 25-Dihydroxyvitamin D3 stimulates the secretion of insulin-like growth factor binding protein 3 (IGFBP-3) by cultured human osteosarcoma cells. Endocrinology 130(2), 1071-1073.
144. L. Mosekilde, et al. (2000) Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia. Bone 26(6), 643-651.
145. E.J. Murray, et al. (1997) E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro. Metabolism 46(9), 1090-1094.
146. R.J. Murrills, et al. (1990) The effects of parathyroid hormone (PTH) and PTH-related peptide on osteoclast resorption of bone slices in vitro: An analysis of pit size and the resorption focus. Endocrinology 127 2648-2653.
147. T. Nakazawa, et al. (2005) Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1–34) on chondrogenesis in a model of experimental fracture healing. Bone 37(5), 711-719.
148. J.M. Nervina, et al. (2006) PGC-1alpha is induced by parathyroid hormone and coactivates Nurr1-mediated promoter activity in osteoblasts. Bone 39(5), 1018-1025.
149. S. Nishida, et al. (1994) Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15 717-723.
150. C.A. O’Brien, et al. (2006) Activation of PTH receptor I in osteocytes suppresses Sost Expression and increases bone mass in transgenic mice. J. Bone Miner. Res. 21(suppl. 1), S4.
151. M. Ogita, et al. (2007) Proliferation and differentiation of periosteal osteoblast progenitors are differentially regulated by sex steroids and intermittent PTH administration. J. Bone Miner. Res 22(suppl. 1), S95.
152. Y. Okada, et al. (2003) Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J. Biol. Chem 278(23), 21258-21266.
153. T. Onishi and K. Hruska (1997) Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology 138(5), 1995-2004.
154. J.E. Onyia, et al. (1995) In vivo, human parathyroid hormone fragment (hPTH 1–34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17 479-484.
155. J.E. Onyia, et al. (2005) Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray. J Cell Biochem 95(2), 403-418.
156. J.E. Onyia, et al. (1997) Parathyroid hormone (1–34) - mediated interleukin-6 induction. J. Cell. Biochem. 67(2), 265-274.
157. J.E. Onyia, et al. (2000) In vivo demonstration that human parathyroid hormone 1–38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J. Bone Miner. Res 15(5), 863-871.
158. J.E. Onyia, et al. (1997) Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. Bone 20(2), 93-100.
159. H. Oxlund (1993) Parathyroid hormone (1–34) and (1–84) stimulate cortical bone formation both from periosteum and endosteum. Calcif. Tissue Int. 53(6), 394-399.
160. I.C. Ozkurt, F.Q. Pirih and S. Tetradis (2004) Parathyroid hormone induces E4bp4 messenger ribonucleic acid expression primarily through cyclic adenosine 3′, 5′-monophosphate signaling in osteoblasts. Endocrinology 145(8), 3696-3703.
161. A.M. Parfitt (1976) The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part I of IV parts: Mechanisms of calcium transfer between blood and bone and their cellular basis: Morphological and kinetic approaches to bone turnover. Metabolism 25(7), 809-844.
162. A.M. Parfitt (1976) The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases. II. PTH and bone cells: Bone turnover and plasma calcium regulation. Metabolism 25(8), 909-955.
163. J. Parsons and J. Potts (1972) Physiology and chemistry of parathyroid hormone. Clin. Endocrinol. Metab 1 33-60.
164. N.C. Partridge, et al. (1981) Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells. Endocrinology 108(1), 213-219.
165. R.C. Pereira and E. Canalis (1999) Parathyroid hormone increases mac25/insulin-like growth factor-binding protein-related protein-1 expression in cultured osteoblasts. Endocrinology 140(5), 1998-2003.
166. R.C. Pereira, D. Durant and E. Canalis (2000) Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts. Am. J. Physiol. Endocrinol. Metab 279(3), E570-E576.
167. G.J. Pettway, et al. (2005) Anabolic actions of PTH (1–34): Use of a novel tissue engineering model to investigate temporal effects on bone. Bone 36(6), 959-970.
168. E. Phelps, et al. (2005) Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3′, 5′-cyclic adenosine monophosphate signaling in osteoblasts. Calcif. Tissue Int. 77(2), 96-103.
169. F.Q. Pirih, et al. (2003) Parathyroid hormone induces the nuclear orphan receptor NOR-1 in osteoblasts. Biochem. Biophys. Res. Commun. 306(1), 144-150.
170. A. Plas, et al. (1994) Characteristics and properties of osteocytes in culture. J. Bone Miner. Res 9(11), 1697-1704.
171. J.H. Pollock, et al. (1996) In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J. Bone Miner. Res 11 754-759.
172. Poole, E. K., et al. (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19(13), 1842-1844.
173. J. Potts, F. Bringhurst, T. Gardella, S. Nussbaum, G. Segre and H. Kronenberg (1995) Parathyroid hormone: Physiology, chemistry, biosynthesis, secretion, metabolism and mode of action. L. DeGroot (Eds) Endocrinology 3rd ed. Philadelphia: Saunders
174. J.T. Potts (2005) Parathyroid hormone: Past and present. J. Endocrinol. 187(3), 311-325.
175. L.I. Pugsley and H. Selye (1933) The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J. Physiol. 79(1), 113-117.
176. L. Qin, et al. (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J. Biol. Chem 280(4), 3104-3111.
177. X. Qin, et al. (1998) Structure-function analysis of the human insulin-like growth factor binding protein-4. J. Biol. Chem 273(36), 23509-23516.
178. L.G. Raisz (1963) Stimulation of bone resorption by parathyroid hormone in tissue culture. Nature 197 1015-1016.
179. L.G. Raisz (1965) Bone resorption in tissue culture. Factors influencing the response to parathyroid hormone. J. Clin. Invest 44 103-116.
180. L.G. Raisz and B.E. Kream (1983) Regulation of bone formation. N. Engl. J. Med 309(1), 29-35.
181. L.G. Raisz and B.E. Kream (1983) Regulation of bone formation (second of two parts). N. Engl. J. Med 309(2), 83-89.
182. A.P. Rehn, et al. (2007) ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing. Bone 41(2), 231-238.
183. I.R. Reid, et al. (1987) Parathyroid hormone acutely elevates intracellular calcium in osteoblastlike cells. Am. J. Physiol. 253(1 Pt 1), E45-E51.
184. D.J. Rickard, et al. (2006) Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 39(6), 1361-1372.
185. W.E. Roberts (1975) Cell kinetic nature and diurnal periodicity of the rat periodontal ligament. Arch. Oral Biol. 20(7), 465-471.
186. G. Sabatakos, et al. (2000) Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med 6(9), 985-990.
187. A. Sakai, et al. (1999) Intermittent administration of human parathyroid hormone (1–34) prevents immobilization-related bone loss by regulating bone marrow capacity for bone cells in ddY mice. J. Bone Miner. Res 14(10), 1691-1699.
188. R. Samadfam, Q. Xia and D. Goltzman (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J. Bone Miner. Res 22(1), 55-63.
189. K. Sawakami, et al. (2006) The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem 281(33), 23698-23711.
190. C. Schmid, et al. (1989) Release of insulin-like growth factor carrier proteins by osteoblasts: Stimulation by estradiol and growth hormone. Biochem. Biophys. Res. Commun. 160(2), 788-794.
191. C. Schmid, et al. (1994) Growth hormone and parathyroid hormone stimulate IGFBP-3 in rat osteoblasts. Am. J. Physiol. Endocrin. Metabol. 267: E226-E233.
192. I.U. Schmidt, H. Dobnig and R.T. Turner (1995) Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136 5127-5134.
193. D.K. Scott, et al. (1992) Parathyroid hormone induces transcription of collagenase in rat osteoblastic cells by a mechanism using cyclic adenosine 3′, 5′-monophosphate and requiring protein synthesis. Mol. Endocrinol 6: 2153-2159.
194. A. Scutt, et al. (1994) Time-dependent effects of parathyroid hormone and prostaglandin E2 on DNA synthesis by periosteal cells from embryonic chick calvaria. Calcif. Tissue Int 55(3), 208-215.
195. T. Seck, et al. (2001) Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur. J. Endocrinol. 145(2), 199-205.
196. M. Semenov, K. Tamai and X. He (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem 280(29), 26770-26775.
197. E. Shimizu, et al. (2007) Parathyroid hormone regulates histone deacetylases in osteoblasts. Ann. N. Y. Acad. Sci 1116 349-353.
198. G.J. Spencer, et al. (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci 119(Pt 7), 1283-1296.
199. D. Stanislaus, V. Devanarayan and J.M. Hock (2000) In vivo comparison of activated protein-1 gene activation in response to human parathyroid hormone (hPTH)(1–34) and hPTH(1–84) in the distal femur metaphyses of young mice. Bone 27(6), 819-826.
200. S.J. Steddon and J. Cunningham (2005) Calcimimetics and calcilytics—Fooling the calcium receptor. Lancet 365(9478), 2237-2239.
201. L.S. Stilgren, et al. (2004) Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: Effect of parathyroidectomy and association with bone metabolism. Bone 35(1), 256-265.
202. N. Suda, et al. (1996) Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J. Cell. Physiol 166 94-104.
203. T. Suda, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev 20(3), 345-357.
204. J.T. Swarthout, et al. (2001) Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C- dependent. J. Biol. Chem 276(10), 7586-7592.
205. P. Szulc, et al. (2001) Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status. J. Clin. Endocrinol. Metab. 86(7), 3162-3165.
206. C.S. Tam, et al. (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 110 506-512.
207. A. Teti, R. Rizzoli and A.Z. Zallone (1991) Parathyroid hormone binding to cultured avian osteoclasts. Biochem. Biophys. Res. Commun. 174 1217-1222.
208. S. Tetradis, O. Bezouglaia and A. Tsingotjidou (2001) Parathyroid hormone induces expression of the nuclear orphan receptor Nurr1 in bone cells. Endocrinology 142(2), 663-670.
209. S. Tetradis, et al. (2001) Regulation of the nuclear orphan receptor Nur77 in bone by parathyroid hormone. Biochem. Biophys. Res. Commun. 281(4), 913-916.
210. S. Tetradis, et al. (1998) Parathyroid hormone induces expression of the inducible cAMP early repressor in osteoblastic MC3T3-E1 cells and mouse calvariae. J. Bone Miner. Res. 13(12), 1846-1851.
211. S. Tetradis, et al. (1997) Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3′, 5′-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 138(9), 3594-3600.
212. S. Tetradis, et al. (1996) Parathyroid hormone induces prostaglandin G/H synthase-2 expression by a cyclic adenosine 3′, 5′-monophosphate-mediated pathway in the murine osteoblastic cell line MC3T3-E1. Endocrinology 137(12), 5435-5440.
213. A.P. Thomas (2000) Sharing calcium opens new avenues of signalling. Nat. Cell Biol. 2(7), E126-E127.
214. T. Tobimatsu, et al. (2006) Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147(5), 2583-2590.
215. A. Tsingotjidou, et al. (2002) Parathyroid hormone induces RGS-2 expression by a cyclic adenosine 3′, 5′-monophosphate-mediated pathway in primary neonatal murine osteoblasts. Bone 30(5), 677-684.
216. R.T. Turner, et al. (1998) Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hind limb-unloaded ovariectomized rats. Endocrinology 139(10), 4086-4091.
217. D.R. Tyson, et al. (2002) PTH induction of transcriptional activity of the cAMP response element-binding protein requires the serine 129 site and glycogen synthase kinase-3 activity, but not casein kinase II sites. Endocrinology 143(2), 674-682.
218. A. Valenta, et al. (2005) Combined treatment with PTH (1–34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 37(1), 87-95.
219. R.L. Van Bezooijen, et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med 199(6), 805-814.
220. Y. Wang, et al. (2007) IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J. Bone Miner. Res 22(9), 1329-1337.
221. Y.H. Wang, Y. Liu and D.W. Rowe (2007) Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am. J. Physiol. Endocrinol. Metab 292(2), E594-E603.
222. Z.-Q. Wang, et al. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360 741-745.
223. P. Watson, et al. (1995) Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16 357-365.
224. P.H. Watson, et al. (1999) Enhanced osteoblast development after continuous infusion of hPTH(1–84) in the rat. Bone 24(2), 89-94.
225. J.E. Wergedal, et al. (2003) Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J. Clin. Endocrinol. Metab 88(12), 5778-5783.
226. J.F. Whitfield, et al. (1998) Comparison of the abilities of human parathyroid hormone (hPTH)-(1–34) and [Leu27]-cyclo(Glu22-Lys26)-hPTH-(1–31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif. Tissue Int 63(5), 423-428.
227. S.K. Winchester, et al. (1999) Regulation of expression of collagenase-3 in normal, differentiating rat osteoblasts. J. Cell. Physiol 181(3), 479-488.
228. D.G. Winkler, et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23), 6267-6276.
229. T.J. Wronski, et al. (1993) Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132 823-831.
230. S. Yakar, et al. (2006) The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 189(2), 289-299.
231. M. Yamaguchi, et al. (2005) Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146(6), 2620-2628.
232. R.W. Young (1962) Cell proliferation and specialization during endochondral osteogenesis in young rats. J. Cell. Biol. 14 357-370.
233. R.W. Young (1964) Specialization of bone cells. Symposium on Bone Biodynamics Boston: Little, Brown and Company
234. W. Zhao, et al. (1999) Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest.103(4), 517-524.
235. W.G. Zhao, et al. (1999) Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest. 103(4), 517-524.
236. K. Ziambaras, et al. (2005) Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray. J Cell Biochem 95(2), 403-418.